在接受经动脉栓塞治疗的肝细胞癌患者中，欧洲肝脏研究学会（EASL）反应和改良实体瘤疗效评价标准（mRECIST）反应对生存有独立影响吗？ - Suppr | 超能文献

Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?

作者信息

Wang Weijuan, Zhao Yan, Han Guohong, Fan Daiming

出版信息

J Hepatol. 2012 Jul;57(1):224-5; author reply 225-6. doi: 10.1016/j.jhep.2012.01.016. Epub 2012 Feb 8.

DOI:10.1016/j.jhep.2012.01.016

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?在接受经动脉栓塞治疗的肝细胞癌患者中，欧洲肝脏研究学会（EASL）反应和改良实体瘤疗效评价标准（mRECIST）反应对生存有独立影响吗？

J Hepatol. 2012 Jul;57(1):224-5; author reply 225-6. doi: 10.1016/j.jhep.2012.01.016. Epub 2012 Feb 8.

2

EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.EASL 和 mRECIST 应答是经动脉栓塞治疗肝细胞癌患者生存的独立预后因素。

J Hepatol. 2011 Dec;55(6):1309-16. doi: 10.1016/j.jhep.2011.03.007. Epub 2011 Apr 15.

3

EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.EASL 和 mRECIST 评价索拉非尼联合经动脉化疗栓塞治疗肝细胞癌的疗效反应可预测患者的生存。

Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.

4

Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.肝移植前经化疗栓塞治疗的肝细胞癌患者，计算机断层扫描显示的肿瘤反应与病理坏死的相关性

Liver Transpl. 2016 Nov;22(11):1491-1500. doi: 10.1002/lt.24615.

5

Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.比较经动脉化疗栓塞治疗肝细胞癌患者肿瘤反应评估方法。

J Hepatol. 2013 Jun;58(6):1181-7. doi: 10.1016/j.jhep.2013.01.039. Epub 2013 Feb 8.

6

Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.基于强化标准的肝细胞癌经动脉化疗栓塞反应评估的最佳测量方式和方法。

J Vasc Interv Radiol. 2013 Mar;24(3):316-25. doi: 10.1016/j.jvir.2012.10.022. Epub 2013 Jan 9.

7

Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.实体瘤反应评估标准（RECIST）标准优于欧洲肝脏研究协会（EASL）标准，在肝癌患者接受肝移植前经动脉化疗栓塞治疗 1 个月随访时，可预测长期生存。

J Vasc Interv Radiol. 2013 Jun;24(6):805-12. doi: 10.1016/j.jvir.2013.01.499. Epub 2013 Apr 4.

8

Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.根据EASL标准和mRECIST标准评估局部区域治疗的肝细胞癌患者客观缓解的预后相关性：一项基于文献的荟萃分析

PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015.

9

Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.哪种缓解标准最有助于预测接受化疗栓塞治疗后的肝细胞癌患者的生存情况？新旧模型的验证研究。

Radiology. 2012 Feb;262(2):708-18. doi: 10.1148/radiol.11110282. Epub 2011 Dec 20.

10

Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma.肝细胞癌患者经导管肝动脉化疗栓塞的放射学反应及临床结局

Liver Int. 2014 Feb;34(2):305-12. doi: 10.1111/liv.12270. Epub 2013 Jul 25.